Head-To-Head Review: Heart Test Laboratories (NASDAQ:HSCS) and Pathfinder Cell Therapy (OTCMKTS:PFND)

Pathfinder Cell Therapy (OTCMKTS:PFND) and Heart Test Laboratories (NASDAQ:HSCS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Institutional & Insider Ownership

17.2% of Heart Test Laboratories shares are owned by institutional investors. 15.1% of Pathfinder Cell Therapy shares are owned by company insiders. Comparatively, 1.8% of Heart Test Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Pathfinder Cell Therapy and Heart Test Laboratories, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pathfinder Cell Therapy	0	0	0	0	0.00
Heart Test Laboratories	0	0	2	0	3.00

Heart Test Laboratories has a consensus target price of $13.50, indicating a potential upside of 264.86%. Given Heart Test Laboratories’ stronger consensus rating and higher possible upside, analysts plainly believe Heart Test Laboratories is more favorable than Pathfinder Cell Therapy.

Profitability

This table compares Pathfinder Cell Therapy and Heart Test Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pathfinder Cell Therapy	N/A	N/A	N/A
Heart Test Laboratories	N/A	-144.12%	-94.48%

Earnings and Valuation

This table compares Pathfinder Cell Therapy and Heart Test Laboratories”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A
Heart Test Laboratories	$14,700.00	246.67	-$6.61 million	($7.91)	-0.47

Pathfinder Cell Therapy has higher earnings, but lower revenue than Heart Test Laboratories.

Summary

Heart Test Laboratories beats Pathfinder Cell Therapy on 5 of the 8 factors compared between the two stocks.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

About Heart Test Laboratories

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.